The effect of stomach contractions and bitter on food intake in healthy volunteers and patients

The influence of erythromycin and bitter administration on ad libitum food intake in healthy volunteers and patients

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2013-004332-29-BE

Enrollment

Registered

2013-10-18

Start date

2013-12-18

Completion date

Unknown

Last updated

2021-05-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

The effect of erythromycin administration on voluntary food intake will be tested in healthy volunteers, obese patients and patients with unexplained weight loss

Interventions

Trade Name: Erythrocine Pharmaceutical Form: Powder for solution for injection/infusion Pharmaceutical form of the placebo: Solution for infusion Route of administration of the placebo: Intravenous dr

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: o BMI>30 kg/m² for the obese volunteers o BMI=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: o Female volunteer is pregnant or breastfeeding o GI diseases, major abdominal surgery o Major psychiatric illnesses o Volunteers that use drugs affecting the GI tract or the central nervous system o Volunteers that suffer from diabetes mellitus o Volunteers suffering from an endocrine disease such as diabetes, Cushing’s disease, Addison’s disease, hypothalamic tumor… o Volunteers that have undergone surgical procedure for weight loss

Design outcomes

Primary

Measure	Time frame
Main Objective: Linking fase 3 contractions and motilin to food intake through the adminsitration of erythromycin, which is a motilin receptor agonist and and induces phase III contractions;Secondary Objective: NA;Primary end point(s): The primary endpoint is to compare food intake between placebo and erythromycin adminsitration;Timepoint(s) of evaluation of this end point: Evaluation at the end of the trial	—

Measure

Time frame

Main Objective: Linking fase 3 contractions and motilin to food intake through the adminsitration of erythromycin, which is a motilin receptor agonist and and induces phase III contractions;Secondary Objective: NA;Primary end point(s): The primary endpoint is to compare food intake between placebo and erythromycin adminsitration;Timepoint(s) of evaluation of this end point: Evaluation at the end of the trial

—

Secondary

Measure	Time frame
Secondary end point(s): NA;Timepoint(s) of evaluation of this end point: NA	—

Countries

Belgium

Contacts

Public ContactEveline Deloose

UZLeuven

eveline.deloose@med.kuleuven.be

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026